抗坏血酸与骨化三醇对单核细胞趋化蛋白-1、一氧化氮、超氧化物歧化酶作为内皮功能障碍标志物的影响:动脉粥样硬化大鼠模型的体内研究

IF 2.6 Q2 PERIPHERAL VASCULAR DISEASE Vascular Health and Risk Management Pub Date : 2023-01-01 DOI:10.2147/VHRM.S401521
Teuku Heriansyah, Herlina Dimiati, Tjut Farahiya Hadi, Dimas Arya Umara, Lian Varis Riandi, Fauzan Fajri, Sukmawan Fajar Santosa, Titin Andri Wihastuti, Kumboyono Kumboyono
{"title":"抗坏血酸与骨化三醇对单核细胞趋化蛋白-1、一氧化氮、超氧化物歧化酶作为内皮功能障碍标志物的影响:动脉粥样硬化大鼠模型的体内研究","authors":"Teuku Heriansyah,&nbsp;Herlina Dimiati,&nbsp;Tjut Farahiya Hadi,&nbsp;Dimas Arya Umara,&nbsp;Lian Varis Riandi,&nbsp;Fauzan Fajri,&nbsp;Sukmawan Fajar Santosa,&nbsp;Titin Andri Wihastuti,&nbsp;Kumboyono Kumboyono","doi":"10.2147/VHRM.S401521","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Ascorbic acid and calcitriol were frequently utilized in conjunction as therapy during the COVID-19 pandemic, and individuals with minor symptoms had notable improvements. There have been a few studies, often with conflicting findings, that examine the use of them for endothelium restoration and numerous clinical trial studies that failed to establish the efficacy. The aim of this study was to find the efficacy of ascorbic acid compared to calcitriol on the inflammatory markers monocyte chemoattractant protein-1 (MCP-1), nitric oxide (NO), and superoxide dismutase (SOD), as protective agents which play an important role in the early stages of atherosclerosis formation. This study was an experimental in vivo study.</p><p><strong>Methods: </strong>The total of 24 male <i>Rattus norvegicus</i> strain Wistar rats were divided into 4 groups, namely: control/normal group (N), atherosclerosis group (DL) given atherogenic diet, atherosclerosis group given atherogenic diet and ascorbic acid (DLC), and atherosclerosis group given atherogenic diet and calcitriol (DLD) treatment for 30 days.</p><p><strong>Results: </strong>Ascorbic acid and calcitriol treatment was significantly effective (<i>P</i><0.05) in lowering expression of MCP-1 and increasing NO and SOD level. Calcitriol was superior to ascorbic acid in increasing SOD (<i>P</i><0.05). There was no significant difference between ascorbic acid and calcitriol in decreasing MCP-1 and increasing NO (<i>P</i>>0.05).</p><p><strong>Discussion: </strong>Both treatments could reduce MCP-1, and increase NO and SOD by increasing antioxidants. In this study calcitriol was superior to ascorbic acid in increasing SOD, but not NO and decreasing MCP-1. According to the theory, it was found that calcitriol through nuclear factor erythroid 2-related factor 2 (Nrf2) causes a direct increase in the amount of SOD. Nrf2 is an emerging regulator of cellular resistance to oxidants.</p><p><strong>Conclusion: </strong>Ascorbic acid and calcitriol treatment was able to reduce MCP-1 and increase NO and SOD in atherosclerosis rat. Calcitriol was significantly superior in increasing SOD levels compared to ascorbic acid.</p>","PeriodicalId":23597,"journal":{"name":"Vascular Health and Risk Management","volume":"19 ","pages":"139-144"},"PeriodicalIF":2.6000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/08/63/vhrm-19-139.PMC10019521.pdf","citationCount":"1","resultStr":"{\"title\":\"Ascorbic Acid vs Calcitriol in Influencing Monocyte Chemoattractant Protein-1, Nitric Oxide, Superoxide Dismutase, as Markers of Endothelial Dysfunction: In Vivo Study in Atherosclerosis Rat Model.\",\"authors\":\"Teuku Heriansyah,&nbsp;Herlina Dimiati,&nbsp;Tjut Farahiya Hadi,&nbsp;Dimas Arya Umara,&nbsp;Lian Varis Riandi,&nbsp;Fauzan Fajri,&nbsp;Sukmawan Fajar Santosa,&nbsp;Titin Andri Wihastuti,&nbsp;Kumboyono Kumboyono\",\"doi\":\"10.2147/VHRM.S401521\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Introduction: </strong>Ascorbic acid and calcitriol were frequently utilized in conjunction as therapy during the COVID-19 pandemic, and individuals with minor symptoms had notable improvements. There have been a few studies, often with conflicting findings, that examine the use of them for endothelium restoration and numerous clinical trial studies that failed to establish the efficacy. The aim of this study was to find the efficacy of ascorbic acid compared to calcitriol on the inflammatory markers monocyte chemoattractant protein-1 (MCP-1), nitric oxide (NO), and superoxide dismutase (SOD), as protective agents which play an important role in the early stages of atherosclerosis formation. This study was an experimental in vivo study.</p><p><strong>Methods: </strong>The total of 24 male <i>Rattus norvegicus</i> strain Wistar rats were divided into 4 groups, namely: control/normal group (N), atherosclerosis group (DL) given atherogenic diet, atherosclerosis group given atherogenic diet and ascorbic acid (DLC), and atherosclerosis group given atherogenic diet and calcitriol (DLD) treatment for 30 days.</p><p><strong>Results: </strong>Ascorbic acid and calcitriol treatment was significantly effective (<i>P</i><0.05) in lowering expression of MCP-1 and increasing NO and SOD level. Calcitriol was superior to ascorbic acid in increasing SOD (<i>P</i><0.05). There was no significant difference between ascorbic acid and calcitriol in decreasing MCP-1 and increasing NO (<i>P</i>>0.05).</p><p><strong>Discussion: </strong>Both treatments could reduce MCP-1, and increase NO and SOD by increasing antioxidants. In this study calcitriol was superior to ascorbic acid in increasing SOD, but not NO and decreasing MCP-1. According to the theory, it was found that calcitriol through nuclear factor erythroid 2-related factor 2 (Nrf2) causes a direct increase in the amount of SOD. Nrf2 is an emerging regulator of cellular resistance to oxidants.</p><p><strong>Conclusion: </strong>Ascorbic acid and calcitriol treatment was able to reduce MCP-1 and increase NO and SOD in atherosclerosis rat. Calcitriol was significantly superior in increasing SOD levels compared to ascorbic acid.</p>\",\"PeriodicalId\":23597,\"journal\":{\"name\":\"Vascular Health and Risk Management\",\"volume\":\"19 \",\"pages\":\"139-144\"},\"PeriodicalIF\":2.6000,\"publicationDate\":\"2023-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/08/63/vhrm-19-139.PMC10019521.pdf\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Vascular Health and Risk Management\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.2147/VHRM.S401521\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"PERIPHERAL VASCULAR DISEASE\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Vascular Health and Risk Management","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2147/VHRM.S401521","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PERIPHERAL VASCULAR DISEASE","Score":null,"Total":0}
引用次数: 1

摘要

在COVID-19大流行期间,抗坏血酸和骨化三醇经常联合使用作为治疗,症状轻微的个体有显着改善。有一些研究,通常有相互矛盾的结果,检验了它们用于内皮细胞修复的使用,以及许多未能确定其功效的临床试验研究。本研究的目的是发现抗坏血酸与骨化三醇相比对炎症标志物单核细胞化学引诱蛋白-1 (MCP-1)、一氧化氮(NO)和超氧化物歧化酶(SOD)的作用,这些保护因子在动脉粥样硬化形成的早期阶段起着重要作用。本研究为实验性体内研究。方法:将24只雄性褐家鼠Wistar大鼠分为4组,分别为:对照组/正常组(N)、动脉粥样硬化组(DL)给予致动脉粥样硬化组(DL)给予致动脉粥样硬化组(DL)给予致动脉粥样硬化组(DLC)给予致动脉粥样硬化组(DLC)给予致动脉粥样硬化组(DLC)给予致动脉粥样硬化组(DLD)给予致动脉粥样硬化组(DLD)给予致动脉粥样硬化组(DLD)治疗30 d。结果:抗坏血酸联合骨化三醇治疗组疗效显著(PPP>0.05)。讨论:两种处理均可通过增加抗氧化剂降低MCP-1,增加NO和SOD。骨化三醇在增加SOD、降低MCP-1方面优于抗坏血酸。根据理论发现骨化三醇通过核因子红细胞2相关因子2 (Nrf2)直接引起SOD的量增加。Nrf2是一种新兴的细胞抗氧化剂调节剂。结论:抗坏血酸和骨化三醇可降低动脉粥样硬化大鼠MCP-1水平,升高NO和SOD水平。骨化三醇在提高SOD水平方面明显优于抗坏血酸。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Ascorbic Acid vs Calcitriol in Influencing Monocyte Chemoattractant Protein-1, Nitric Oxide, Superoxide Dismutase, as Markers of Endothelial Dysfunction: In Vivo Study in Atherosclerosis Rat Model.

Introduction: Ascorbic acid and calcitriol were frequently utilized in conjunction as therapy during the COVID-19 pandemic, and individuals with minor symptoms had notable improvements. There have been a few studies, often with conflicting findings, that examine the use of them for endothelium restoration and numerous clinical trial studies that failed to establish the efficacy. The aim of this study was to find the efficacy of ascorbic acid compared to calcitriol on the inflammatory markers monocyte chemoattractant protein-1 (MCP-1), nitric oxide (NO), and superoxide dismutase (SOD), as protective agents which play an important role in the early stages of atherosclerosis formation. This study was an experimental in vivo study.

Methods: The total of 24 male Rattus norvegicus strain Wistar rats were divided into 4 groups, namely: control/normal group (N), atherosclerosis group (DL) given atherogenic diet, atherosclerosis group given atherogenic diet and ascorbic acid (DLC), and atherosclerosis group given atherogenic diet and calcitriol (DLD) treatment for 30 days.

Results: Ascorbic acid and calcitriol treatment was significantly effective (P<0.05) in lowering expression of MCP-1 and increasing NO and SOD level. Calcitriol was superior to ascorbic acid in increasing SOD (P<0.05). There was no significant difference between ascorbic acid and calcitriol in decreasing MCP-1 and increasing NO (P>0.05).

Discussion: Both treatments could reduce MCP-1, and increase NO and SOD by increasing antioxidants. In this study calcitriol was superior to ascorbic acid in increasing SOD, but not NO and decreasing MCP-1. According to the theory, it was found that calcitriol through nuclear factor erythroid 2-related factor 2 (Nrf2) causes a direct increase in the amount of SOD. Nrf2 is an emerging regulator of cellular resistance to oxidants.

Conclusion: Ascorbic acid and calcitriol treatment was able to reduce MCP-1 and increase NO and SOD in atherosclerosis rat. Calcitriol was significantly superior in increasing SOD levels compared to ascorbic acid.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Vascular Health and Risk Management
Vascular Health and Risk Management PERIPHERAL VASCULAR DISEASE-
CiteScore
4.20
自引率
3.40%
发文量
109
审稿时长
16 weeks
期刊介绍: An international, peer-reviewed journal of therapeutics and risk management, focusing on concise rapid reporting of clinical studies on the processes involved in the maintenance of vascular health; the monitoring, prevention, and treatment of vascular disease and its sequelae; and the involvement of metabolic disorders, particularly diabetes. In addition, the journal will also seek to define drug usage in terms of ultimate uptake and acceptance by the patient and healthcare professional.
期刊最新文献
Characteristic of 24-Hour Blood Pressure Dipping Patterns in Hypertensive Stroke Patients. Assessment of Coronary Artery Disease in Non-Valvular Atrial Fibrillation: Is This Light at the End of the Tunnel? Misdiagnosis of Chronic Heart Failure in Patients with Type 2 Diabetes Mellitus in Primary Care: A Report of Two Cases and Literature Review. Clinical Accuracy of the G.LAB MD41A0 Upper Arm Blood Pressure Monitor in Pregnancy and Pre-Eclampsia Using the AAMI/ESH/ISO as Reference Standard. Fatal Acute Limb Ischemia Due to Catastrophic Late Endograft Infection and Adjacent Arterial Infection After Endovascular Aneurysm Repair - A Case Report.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1